Chemical Engineering @ChemengFiles.Com

Cambridge Laboratories Limited has announced that its main product, Tetrabenazine, (known as NITOMAN (R) in Germany and other key territories in Europe and XENAZINE (R) in UK, U.S. and other markets) has received approval from the market in Spain through the Spanish Agency of Medicines and Health Products.

The company has also recently announced that it has signed distribution agreements for Tetrabenazine in Finland and Taiwan, in addition to renew existing agreements enAustraliay New Zealand.

Tetrabenazine was like NITOMAN market in Spain (R) through marketing partner of Cambridge, UCB, until he achieves the success of all procedures related. Has received approval for the treatment of diseases of movement associated with Huntington's disease, a disease for which there are important medical needs not covered.

Cambridge has recently renegotiated its agreements with Spain and in Portugal UCB, UCB providing exclusive marketing rights for ten years on Tetrabenazine in Spain. UCB, a global biopharmaceutical company, focuses on severe diseases in three therapeutic areas - inflammation, oncology and neurology. The terms have been renegotiated after the acquisition occurred on the part of the UCB Celltech, a former partner of Cambridge in Spain yPortugal, and the more recent merger with UCB Schwarz Pharma.

UCB is in the process of implementing pricing and reimbursement in Spain and expects to complete this procedure in the first half of 2009.